Abstract
Background & AimsQuite a few studies had investigated the correlation between CXC chemokine receptor 2 (CXCR2) and cancer. This meta-analysis was aimed to comprehensively summarize the previous studies and to explore the prognostic value of CXCR2 in patients with cancer.Materials and MethodsAn adequate literature search in EMBASE and PubMed was conducted. Articles in English which have reported CXCR2 expression in patients and enough data to calculate hazard ratio (HR) were included. Effect estimates were analyzed with Review Manager 5.2. The endpoint was overall survival (OS) and recurrence-free survival (RFS).ResultTwelve studies from 10 publications with a total of 2,461 patients were identified. It was shown that high level of CXCR2 was significantly associated with poorer overall survival (OS) (HR = 1.69, 95% CI = 1.46–1.96, p < 0.0001, I2 = 45%) and RFS (HR = 1.50, 95% CI = 1.25–1.80, p < 0.0001, I2 = 6%). The analyses of different analysis models (univariate or multivariate models), sample size (< 300 or ≥ 300) and ethnicity (Asian and Caucasian) have indicated the negative impact of CXCR2 over-expression on survival of patients with cancer. Stratified by cancer type, high-expression of CXCR2 was associated with unfavorable OS in laryngeal squamous cell carcinoma, lung cancer, pancreatic ductal carcinoma, clear-cell renal cell carcinoma and hepatocellular carcinoma; however, there was significant difference between high- and low-expression of CXCR2 in digestive tract cancer (esophageal adenocarcinoma and squamous cell carcinoma procession, resected esophageal carcinoma, esophageal cancer and gastric cancer).ConclusionsCXCR2 is an unfavorable predictor in terms of OS and RFS in patients with cancer except for digestive tract cancer and is related with poorer prognostic.
Highlights
Cancer is the leading cause of death in both developing and developed countries
CXC chemokine receptor 2 (CXCR2) is an unfavorable predictor in terms of overall survival (OS) and recurrence-free survival (RFS) in patients with cancer except for digestive tract cancer and is related with poorer prognostic
The rest 45 articles were retrieved for full-text review, from which 33 were excluded: 25 not focusing on the expression of CXCR2 in cancer patients and 8 without efficient data on the expression of CXCR2 or overall survival (OS) or recurrence-free survival (RFS) to calculate hazard ratio (HR)
Summary
Cancer is the leading cause of death in both developing and developed countries. Both incidence and mortality of cancer grow rapidly for increasing population, senility, and unhealthy adoption of lifestyle behaviors [1]. It is identified that surgery, radiotherapy and chemotherapy are utilized as standard treatments in cancer cases. Quite a few studies had investigated the correlation between CXC chemokine receptor 2 (CXCR2) and cancer. This meta-analysis was aimed to comprehensively summarize the previous studies and to explore the prognostic value of CXCR2 in patients with cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
